Cart
sales@molnova.com
Idelalisib
CAS No. 870281-82-6
Idelalisib ( CAL-101;GS-1101;GS1101;GS1101 )
Catalog No. M16323 CAS No. 870281-82-6
Idelalisib (CAL-101, GS-1101) is a potent, selective inhibitor of PI3K p110δ with IC50 of 2.5 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 27 | In Stock |
|
| 10MG | 39 | In Stock |
|
| 25MG | 61 | In Stock |
|
| 50MG | 77 | In Stock |
|
| 100MG | 99 | In Stock |
|
| 200MG | 129 | In Stock |
|
| 500MG | 213 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameIdelalisib
-
NoteResearch use only, not for human use.
-
Brief DescriptionIdelalisib (CAL-101, GS-1101) is a potent, selective inhibitor of PI3K p110δ with IC50 of 2.5 nM.
-
DescriptionIdelalisib (CAL-101, GS-1101) is a potent, selective inhibitor of PI3K p110δ with IC50 of 2.5 nM, 40- to 300-fold selectivity over other class I PI3Ks (p110α/βγ, IC50=820/565/89nM), and 400- to 4000-fold over C2β, hVPS34, DNA-PK, and mTOR; blocks FcRI p110δ-mediated CD63 expression in basophils with an EC50 of 8 nM; blocks constitutive PI3K signaling, resulting in decreased phosphorylation of Akt and other downstream effectors, an increase in PARP and caspase cleavage and an induction of apoptosis in multiple B-cell malignancies.Blood Cancer Approved
-
SynonymsCAL-101;GS-1101;GS1101;GS1101
-
PathwayPI3K/Akt/mTOR signaling
-
TargetPI3K
-
RecptorhVps34;p110α;p110β;p110γ;p110δ
-
Research AreaCancer
-
IndicationBlood cancer
Chemical Information
-
CAS Number870281-82-6
-
Formula Weight415.42
-
Molecular FormulaC22H18FN7O
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 59.7 mg/mL
-
SMILESO=C1N(C2=CC=CC=C2)C([C@@H](NC3=C4N=CNC4=NC=N3)CC)=NC5=C1C(F)=CC=C5
-
Chemical Name4(3H)-Quinazolinone, 5-fluoro-3-phenyl-2-[(1S)-1-(9H-purin-6-ylamino)propyl]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Hoellenriegel J, et al. Blood. 2011 Sep 29;118(13):3603-12.
2. Herman SE, et al. Blood. 2010 Sep 23;116(12):2078-88.
3. Lannutti BJ, et al. Blood. 2011 Jan 13;117(2):591-4.
4. Bodo J, et al. Br J Haematol. 2013 Oct;163(1):72-80.
2. Herman SE, et al. Blood. 2010 Sep 23;116(12):2078-88.
3. Lannutti BJ, et al. Blood. 2011 Jan 13;117(2):591-4.
4. Bodo J, et al. Br J Haematol. 2013 Oct;163(1):72-80.
molnova catalog
related products
-
APY0201
APY0201 is a potent, highly selective, ATP-competitive PIKfyve inhibitor (IC50=5.2 nM) that interrupts the conversion of phosphatidylinositol 3-phosphate (PtdIns3P) to PtdIns(3,5)P2.
-
GSK-2292767
GSK-2269557 is a highly potent and selective inhibitor of PI3Kδ (pKi=10.1).
-
SF2523
A novel potent, dual inhibitor of PI3K and BRD4 with IC50 of 241, 34, 158 nM for BRD4 (BD1), PI3Kα and PI3Kγ, respectively.
